Business

Mylan has launched the Sirdupla salmeterol xinafoate/fluticasone propionate MDI, its bioequivalent version of GlaxoSmithKline's Seretide (Advair) Evohaler, for the treatment of asthma in the UK, the company announced. The product, which is being marketed in 125/25 mcg and 250/25 mcg versions, is manufactured by 3M Drug Delivery Systems. Mylan President Rajiv Malik … [Read more...] about Mylan launches Sirdupla salmeterol/fluticasone MDI in the UK

PARI Respiratory Equipment has announced that its Kitabis Pak, tobramycin inhalation solution packaged with a PARI LC Plus nebulizer for the treatment of cystic fibrosis, has won a 2015 American Package Design Award, presented by Graphic Design USA. The FDA approved Kitabis Pak in December 2014 and rated the product as a therapeutic equivalent of TOBI in March … [Read more...] about Kitabis Pak wins American Package Design Award

The National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a 3-year, $3 million grant to Pulmotect for clinical studies of its PUL-042 inhaled therapy for the treatment of respiratory infections in cancer patients whose immune systems have been compromised, the company has announced. In 2012, Pulmotect received a a $7.1 million … [Read more...] about Pulmotect gets $3 million grant for development of inhaled therapy for respiratory infections in cancer patients

Generex Biotechnology has announced an agreement with NHTherapeutics to co-develop a formulation of leuprolide for delivery by Generex's RapidMist buccal aerosol technology. Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which is currently approved at higher dosage levels for the treatment of conditions such as prostate cancer and endometriosis; NHT is … [Read more...] about Generex to co-develop buccal aerosol formulation of leuprolide for NHTherapeutics

Danish inhaled drug developer Serendex has announced that it has met a number of milestones this year in preparation for clinical development of its portfolio. According to Serendex, in the first quarter of 2015, the company obtained a GMP certificate to allow it to manufacture its own clinical trial supplies and has initiated a Phase 1 clinical trial of its Molgradex … [Read more...] about Inhaled drug developer Serendex says that it is prepared for clinical trials

Inhaled drug developer Prosonix will be acquired by Circassia Pharmaceuticals for a total of £100 million in cash, the company said. Of that total, £70 million will be paid up front, with an additional £30 million "on the achievement of a near term milestone." In September 2014, Prosonix submitted an MAA for its PSX1001 generic fluticasone propionate MDI to the … [Read more...] about Prosonix to be acquired by Circassia Pharmaceuticals for up to £100 million

Pharmaxis has announced that beginning in June 2015, Chiesi Farmaceutici will take over the commercialization of the Bronchitol mannitol DPI for the treatment of cystic fibrosis in the UK, Ireland, and Germany. Additionally, Pharmaxis said that is ending its commercialization agreement with Quintiles, which was announced in 2011 and, for the time being, will … [Read more...] about Chiesi to commercialize Bronchitol in the UK, Ireland, and Germany

Actavis has announced that it is relaunching 0.25 and 0.5 mg vials of budesonide inhalation suspension, a generic version of AstraZeneca's Pulmicort Respules, after the United States Court of Appeals for the Federal Circuit lifted an injunction preventing Actavis from marketing the product. The court upheld a lower court's determination that US Patent No. 7,524,834, … [Read more...] about Appeals court confirms Pulmicort Respules patent invalid, Actavis re-launches its generic version

Pennsylvania-based Egalet Corporation has announced that it will begin promoting Sprix ketorolac tromethamine nasal spray in the second quarter of 2015. Sprix is a non-steroidal anti-inflammatory drug (NSAID) for the short-term treatment of moderate to moderately severe pain, which was acquired by Egalet from Daiichi Sankyo subsidiary Luitpold Pharmaceuticals earlier … [Read more...] about Egalet to begin promoting Sprix nasal spray

California-based InCarda Therapeutics (formerly Pleiades Cardio-Therapeutics) has announced that it raised over $5 million with the possibility of an additional $1.5 million in a private financing round led by Morningside Venture. According to the company, it will use the proceeds for development of an inhaled therapy for paroxysmal atrial fibrillation. InCarda … [Read more...] about InCarda raises more than $5 million for development of inhaled cardiac drugs